Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Point of Care Infectious Disease Testing Market
5.1. COVID-19 Landscape: Point of Care Infectious Disease Testing Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Point of Care Infectious Disease Testing Market, By Disease
8.1. Point of Care Infectious Disease Testing Market, by Disease, 2022-2030
8.1.1 HIV POC
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Clostridium difficile POC
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. HBV POC
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Pneumonia or Streptococcus associated infections
8.1.4.1. Market Revenue and Forecast (2017-2030)
8.1.5. Respiratory syncytial virus (RSV) POC
8.1.5.1. Market Revenue and Forecast (2017-2030)
8.1.6. HPV POC
8.1.6.1. Market Revenue and Forecast (2017-2030)
8.1.7. Influenza/Flu POC
8.1.7.1. Market Revenue and Forecast (2017-2030)
8.1.8. HCV POC
8.1.8.1. Market Revenue and Forecast (2017-2030)
8.1.9. MRSA POC
8.1.9.1. Market Revenue and Forecast (2017-2030)
8.1.10. TB and drug-resistant TB POC
8.1.10.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Point of Care Infectious Disease Testing Market, By Technique
9.1. Point of Care Infectious Disease Testing Market, by Technique, 2022-2030
9.1.1. Lateral Flow
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Agglutination Assays
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Flow-Through Test
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Molecular Diagnostics
9.1.4.1. Market Revenue and Forecast (2017-2030)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Point of Care Infectious Disease Testing Market, By End-Use
10.1. Point of Care Infectious Disease Testing Market, by End-Use, 2022-2030
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Clinics
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Home
10.1.3.1. Market Revenue and Forecast (2017-2030)
10.1.4. Assisted Living Healthcare Facilities
10.1.4.1. Market Revenue and Forecast (2017-2030)
10.1.5. Laboratories
10.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Point of Care Infectious Disease Testing Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Disease (2017-2030)
11.1.2. Market Revenue and Forecast, by Technique (2017-2030)
11.1.3. Market Revenue and Forecast, by End-Use (2017-2030)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Disease (2017-2030)
11.1.4.2. Market Revenue and Forecast, by Technique (2017-2030)
11.1.4.3. Market Revenue and Forecast, by End-Use (2017-2030)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Disease (2017-2030)
11.1.5.2. Market Revenue and Forecast, by Technique (2017-2030)
11.1.5.3. Market Revenue and Forecast, by End-Use (2017-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Disease (2017-2030)
11.2.2. Market Revenue and Forecast, by Technique (2017-2030)
11.2.3. Market Revenue and Forecast, by End-Use (2017-2030)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Disease (2017-2030)
11.2.4.2. Market Revenue and Forecast, by Technique (2017-2030)
11.2.4.3. Market Revenue and Forecast, by End-Use (2017-2030)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Disease (2017-2030)
11.2.5.2. Market Revenue and Forecast, by Technique (2017-2030)
11.2.5.3. Market Revenue and Forecast, by End-Use (2017-2030)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Disease (2017-2030)
11.2.6.2. Market Revenue and Forecast, by Technique (2017-2030)
11.2.6.3. Market Revenue and Forecast, by End-Use (2017-2030)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Disease (2017-2030)
11.2.7.2. Market Revenue and Forecast, by Technique (2017-2030)
11.2.7.3. Market Revenue and Forecast, by End-Use (2017-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Disease (2017-2030)
11.3.2. Market Revenue and Forecast, by Technique (2017-2030)
11.3.3. Market Revenue and Forecast, by End-Use (2017-2030)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Disease (2017-2030)
11.3.4.2. Market Revenue and Forecast, by Technique (2017-2030)
11.3.4.3. Market Revenue and Forecast, by End-Use (2017-2030)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Disease (2017-2030)
11.3.5.2. Market Revenue and Forecast, by Technique (2017-2030)
11.3.5.3. Market Revenue and Forecast, by End-Use (2017-2030)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Disease (2017-2030)
11.3.6.2. Market Revenue and Forecast, by Technique (2017-2030)
11.3.6.3. Market Revenue and Forecast, by End-Use (2017-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Disease (2017-2030)
11.3.7.2. Market Revenue and Forecast, by Technique (2017-2030)
11.3.7.3. Market Revenue and Forecast, by End-Use (2017-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Disease (2017-2030)
11.4.2. Market Revenue and Forecast, by Technique (2017-2030)
11.4.3. Market Revenue and Forecast, by End-Use (2017-2030)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Disease (2017-2030)
11.4.4.2. Market Revenue and Forecast, by Technique (2017-2030)
11.4.4.3. Market Revenue and Forecast, by End-Use (2017-2030)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Disease (2017-2030)
11.4.5.2. Market Revenue and Forecast, by Technique (2017-2030)
11.4.5.3. Market Revenue and Forecast, by End-Use (2017-2030)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Disease (2017-2030)
11.4.6.2. Market Revenue and Forecast, by Technique (2017-2030)
11.4.6.3. Market Revenue and Forecast, by End-Use (2017-2030)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Disease (2017-2030)
11.4.7.2. Market Revenue and Forecast, by Technique (2017-2030)
11.4.7.3. Market Revenue and Forecast, by End-Use (2017-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Disease (2017-2030)
11.5.2. Market Revenue and Forecast, by Technique (2017-2030)
11.5.3. Market Revenue and Forecast, by End-Use (2017-2030)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Disease (2017-2030)
11.5.4.2. Market Revenue and Forecast, by Technique (2017-2030)
11.5.4.3. Market Revenue and Forecast, by End-Use (2017-2030)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Disease (2017-2030)
11.5.5.2. Market Revenue and Forecast, by Technique (2017-2030)
11.5.5.3. Market Revenue and Forecast, by End-Use (2017-2030)
Chapter 12. Company Profiles
12.1. Alere
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Thermo Fisher Scientific Inc
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. F. Hoffmann-La Roche Ltd
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Siemens Healthineers
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. BD & Company
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Chembio Diagnostics Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Trinity Biotech
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Cardinal Health
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Quest Diagnostics Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Bio-Rad Labs Inc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms